A study highlighted the accuracy of three leading continuous glucose monitors (CGM), including systems from Abbott and Dexcom.

For 2025, Insulet expects revenue growth between 16% and 20%. It projects Omnipod sales to increase by 17%-21%.

Blue Cross Blue Shield of Massachusetts announced that it expanded its care options for members with diabetes.

Third-quarter results for Medtronic (NYSE:MDT) included a timeline for a planned label expansion for its automated insulin ...